Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?

I prefer NOT to extrapolate results, given that BTKis have unique spectra of kinase activities ("kinomes"), different PK/PD properties (such as half life), different adherence rates and dosing schedules, and have different synergistic (especially in a complex immune context that we are committing to...

I think the main question here is whether AV can be extrapolated to ZV, since there is already phase 3 data with IV, and I do not think it would be appropriate to extrapolate to a non-covalent BTKi. I think it is very likely that ZV is as effective as AV, but there are not many clinical scenarios wh...

Indirect comparisons, including network meta-analyses and matching-adjusted indirect comparisons, suggest that zanubrutinib monotherapy may offer superior progression-free survival compared to fixed-duration acalabrutinib–venetoclax in low-risk, treatment-naïve CLL. However, these analyses rely on a...

There are data for each BTKi with ven in first line, but the datasets are all unique. Personally, I would not use ibrutinib for safety reasons, although there is a lot of data. Zanubrutinib venetoclax has data from SEQUOIA as an MRD-driven regimen, but most patients stay on the zanu. I have started ...

I think zan is better than acal and less toxic, i.e., fewer headaches.

Await phase III data, but I won't wait.

I have an alternative regimen that I am confident can cure CLL as well as MCL FL and MZL; published, phase II completed. The regimen requires close attention to monitoring CBC and dose adju...